Cosmos Health stock fell 9.03 percent as revenue growth continued

Published on 10/06/2026 at 14:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cosmos Health stock posted Q2 revenue of USD 18.99 million, up 28.8 percent year over year. CosmoFarm's run rate topped USD 60 million on September 29, 2026.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health stock (ISIN US2214133058) was last at USD 0.3457 on Nasdaq on October 5, 2026, at 4:00 p.m. ET, down 9.03 percent from USD 0.3800. The move came as the healthcare group highlighted CosmoFarm's record second-quarter performance and expansion capacity in a September 29 release from Newswire.

CosmoFarm exceeds USD 60 million

CosmoFarm generated more than USD 15 million in Q2 2026 revenue, putting its annualized run rate above USD 60 million, according to Newswire on September 29, 2026. The release also said the subsidiary served more than 1,500 pharmacies, including more than 360 daily-served pharmacies, and could add USD 40 million or more in annual revenue capacity through automation and artificial intelligence.

The comparison is substantial: CosmoFarm's annualized run rate is more than four times its fiscal 2017 sales of approximately USD 14 million, the last full year before Cosmos Health acquired the business. During 2025, revenue per customer rose 12 percent, profitability per customer increased 14 percent and the active customer base grew 20 percent, the company said through Newswire.

Q2 revenue rises 28.8 percent

Consolidated Q2 2026 revenue reached USD 18.99 million, up 28.8 percent from the prior-year quarter, while first-half revenue rose 29.7 percent to USD 36.91 million, according to Yahoo Finance. Adjusted Q2 gross profit increased 58.4 percent and adjusted gross margin expanded 165 basis points to 9.54 percent.

The operating picture still carries pressure. Q2 operating profit was negative USD 2.93 million, net income was negative USD 6.09 million and diluted EPS was negative USD 0.10, based on the Q2 2026 financial statement. The growth story therefore depends on converting distribution scale and contract manufacturing capacity into sustained consolidated profitability.

Sell consensus meets a low share price

MarketBeat lists a Sell consensus for Cosmos Health based on one research report, with no published price target, according to MarketBeat. That cautious view contrasts with the company's 2029 targets of USD 200.6 million in revenue, USD 71.2 million in gross profit, adjusted EBITDA of USD 44.2 million and net income of USD 31.0 million.

Cosmos Health stock stays below USD 1.32

COSM's October 5 reference price of USD 0.3457 stood 73.8 percent below the Nasdaq 52-week high of USD 1.3200 and above the 52-week low of USD 0.1616. For investors, the central test is whether the 28.8 percent quarterly revenue increase can narrow the gap between operating growth and negative earnings.